Hemab Therapeutics Holdings, Inc. (COAG)

Equity Details

Price & Market Data

Price: $27.84

Daily Change: +$1.95 / 7.00%

Daily Range: $26.75 - $33.43

Market Cap: $1,300,278,528

Daily Volume: 270,826

Performance Metrics

1 Week: -6.26%

1 Month: -16.13%

3 Months: -16.13%

6 Months: -16.13%

1 Year: -16.13%

YTD: -16.13%

About Hemab Therapeutics Holdings, Inc. (COAG)

A complete financial picture of Hemab Therapeutics Holdings, Inc. (COAG). Current price: 27.84, daily change: +$1.95 / 7.00%. Market cap: 1,300,278,528. Performance over 1-month and 6-month periods.

Company Details

Employees: 72

Sector: Health technology

Industry: Biotechnology

Country: United States

Details

Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.

Selected stocks

Idea Acquisition Corp. (IACO)

Janus Living, Inc. (JAN)

JATT II Acquisition Corp (JATT)

Green Circle Decarbonize Technology Limited (GCDT)

Rare Earths Americas, Inc. (REA)